Characterization of Prostate Cancer Organoids

Using models from the LuCaP series as well as those generated at the National Cancer Institute, we have established organoids for in vitro mechanistic testing, including drug screening and genetic manipulation. The major findings from these continuing studies is the durability of organoids for maintaining complex subpopulation and intratumoral heterogeneity and the parallels between in vitro testing and patient outcomes. Existing data from prior releases includes whole-genome sequencing, whole-exome sequencing, single-cell and bulk RNA-seq, single-cell ATAC-seq, and SNP array. New data in this release is ChIP-seq data from three models and RNA-seq data from one model.

• Study Design:
  • Case Set
• Study Type:
  • Case Set
• dbGaP estimated ancestry using GRAF-pop
• Total number of consented subjects: 34
• Subject Sample Telemetry Report (SSTR)

• BioProject
• PubMed
• Sequence Read Archive
• BioSample
• GEO
• Gene
• PMC

• Primary Phenotype: Prostatic Neoplasms

• AR
• CD276

• Principal Investigator
  • Kathleeen Kelly. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• Co-Investigator
  • Adam Sowalsky. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.